— Published date: 9/18/2025
Value Proposition: Single chain RANK ligand that can selectively inhibit pathological bone loss.
Technology Description
Researchers at Washington University in St. Louis have developed a genetically engineered mutant RANKL protein that prevents bone loss by selective…
— Published Date: 6/3/2025
Value Proposition: System that employs gut microbe strains engineered with therapeutic enzymes to treat chronic gut conditions.
Technology Description
Researchers at Washington University in St. Louis have developed a hypervesiculating Bacteroides theatiotaomicron (Bt) …
— Published Date: 5/14/2025
Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects.
Technology Description
R…
— Published Date: 5/13/2025
Value Proposition: An innovative therapy leveraging unique chimeric antigen receptors (CAR) to specifically target Fc receptor-like 5 (FCRL5), enabling the precise elimination of FCRL5-expressing cells to treat multiple myeloma and other cancers.
Technology Description
…
— Published Date: 12/21/24
Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments.
Technology Description
Researchers at Washington University…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
